BioVie Inc. stock is down -46.65% since 30 days ago. The next earnings date is Feb 9, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 40% of the previous 9 December’s closed higher than November. In the last 5 Unusual Options Trades, there were 4 PUTs, 1 CALL. 100% of analysts rate it a buy.
|Date & Time||Expiration Date||Strike Price||Trade Type||Size||Open Interest|
|31 Oct 15:48||19 Jan, 2024||2.50||7059|
|31 Oct 17:27||19 Jan, 2024||2.50||7059|
|22 Nov 16:12||19 Jan, 2024||10.00||0|
|22 Nov 17:14||19 Jan, 2024||12.50||1149|
|29 Nov 14:45||19 Jan, 2024||5.00||963|
BioVie Inc. engages in the discovery, development, and commercialization of drugs therapies in the United States. Its products in pipeline include BIV201, which completed Phase IIa clinical trial for the treatment of ascites due to chronic liver cirrhosis; and NE3107, which is in Phase III clinical trials for Alzheimer's, Parkinson's and multiple myeloma and prostate cancer.